frequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. through the controlled activation of progenitor cells, frequency enables disease modification without the complexity of genetic engineering. our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the u.s. alone.
Company profile
Ticker
KRRO, FREQ
Exchange
Website
CEO
David L. Lucchino
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Frequency Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Korro Bio Ops, Inc. • Korro Mass Securities, Inc. • Frequency Therapeutics Pty Ltd • Frequency Therapeutics Securities Corporation ...
IRS number
472324450
KRRO stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
28 Mar 24
POS AM
Prospectus update (post-effective amendment)
26 Mar 24
S-8
Registration of securities for employees
26 Mar 24
8-K
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress
26 Mar 24
10-K
2023 FY
Annual report
26 Mar 24
424B3
Prospectus supplement
9 Jan 24
8-K
Other Events
9 Jan 24
EFFECT
Notice of effectiveness
26 Dec 23
424B3
Prospectus supplement
22 Dec 23
CORRESP
Correspondence with SEC
21 Dec 23
Latest ownership filings
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
Cormorant Asset Management, LP
14 Feb 24
SC 13G
EVENTIDE ASSET MANAGEMENT, LLC
14 Feb 24
SC 13G
FMR LLC
9 Feb 24
4
Rachel Meyers
29 Nov 23
3
Rachel Meyers
29 Nov 23
4
David L. Lucchino
27 Nov 23
144
Notice of proposed sale of securities
22 Nov 23
4
David L. Lucchino
22 Nov 23
144
Notice of proposed sale of securities
20 Nov 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 43.69 mm | 43.69 mm | 43.69 mm | 43.69 mm | 43.69 mm | 43.69 mm |
Cash burn (monthly) | (no burn) | 154.58 k | 4.22 mm | 5.27 mm | 1.60 mm | 3.58 mm |
Cash used (since last report) | n/a | 922.14 k | 25.18 mm | 31.42 mm | 9.55 mm | 21.36 mm |
Cash remaining | n/a | 42.77 mm | 18.51 mm | 12.27 mm | 34.14 mm | 22.33 mm |
Runway (months of cash) | n/a | 276.7 | 4.4 | 2.3 | 21.3 | 6.2 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 40 |
Opened positions | 7 |
Closed positions | 6 |
Increased positions | 9 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 12.34 bn |
Total shares | 10.60 mm |
Total puts | 0.00 |
Total calls | 2.40 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Eventide Asset Managment | 3.60 mm | $10.00 bn |
Vanguard | 1.70 mm | $630.66 mm |
Adage Capital Partners GP, L.L.C. | 1.20 mm | $444.00 mm |
BLK Blackrock | 1.17 mm | $432.78 mm |
Citadel Advisors | 1.08 mm | $395.57 mm |
Renaissance Technologies | 431.70 k | $160.00 k |
Geode Capital Management | 327.71 k | $120.00 mm |
GS Goldman Sachs | 212.08 k | $78.47 mm |
Acadian Asset Management | 140.95 k | $50.00 k |
STT State Street | 125.03 k | $45.77 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Nov 23 | Rachel Meyers | Stock Option Common Stock | Grant | Acquire A | No | No | 37.5 | 12,551 | 470.66 k | 12,551 |
22 Nov 23 | Lucchino David L. | Common Stock | Sell | Dispose S | No | No | 38.8195 | 202 | 7.84 k | 22,150 |
22 Nov 23 | Lucchino David L. | Common Stock | Sell | Dispose S | No | No | 37.9844 | 614 | 23.32 k | 22,352 |
22 Nov 23 | Lucchino David L. | Common Stock | Sell | Dispose S | No | No | 36.7391 | 230 | 8.45 k | 22,966 |
22 Nov 23 | Lucchino David L. | Common Stock | Sell | Dispose S | No | No | 35.9873 | 110 | 3.96 k | 23,196 |
3 Nov 23 | Todd Chappell | Stock Option Common Stock | Grant | Acquire A | No | No | 14.98 | 62,651 | 938.51 k | 62,651 |
3 Nov 23 | Todd Chappell | Stock Option Common Stock | Grant | Acquire A | No | No | 20.94 | 5,128 | 107.38 k | 5,128 |
3 Nov 23 | Todd Chappell | Stock Option Common Stock | Grant | Acquire A | No | No | 22.75 | 4,968 | 113.02 k | 4,968 |
3 Nov 23 | Todd Chappell | Stock Option Common Stock | Grant | Acquire A | No | No | 11.68 | 13,625 | 159.14 k | 13,625 |
News
HC Wainwright & Co. Maintains Buy on Korro Bio, Raises Price Target to $115
28 Mar 24
Piper Sandler Maintains Overweight on Korro Bio, Maintains $180 Price Target
27 Mar 24
RBC Capital Maintains Outperform on Korro Bio, Raises Price Target to $90
27 Mar 24
Korro FY23 EPS $(53.08) Vs $(227.42) YoY
26 Mar 24
BMO Capital Reiterates Outperform on Korro Bio, Maintains $120 Price Target
26 Mar 24
Press releases
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress
26 Mar 24
Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio
18 Jan 24
Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference
4 Jan 24